Last reviewed · How we verify
Cyclosporin Capsules
Cyclosporin Capsules inhibit calcineurin, preventing T-cell activation and proliferation.
Cyclosporin Capsules inhibit calcineurin, preventing T-cell activation and proliferation. Used for Prevention of organ rejection in transplant patients.
At a glance
| Generic name | Cyclosporin Capsules |
|---|---|
| Sponsor | Shanghai JMT-Bio Inc. |
| Drug class | Calcineurin inhibitor |
| Target | Calcineurin |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
This mechanism is crucial in preventing the body's immune response from attacking transplanted organs. By inhibiting calcineurin, Cyclosporin Capsules reduce the risk of organ rejection in transplant patients.
Approved indications
- Prevention of organ rejection in transplant patients
Common side effects
- Nephrotoxicity
- Hypertension
- Diabetes mellitus
- Hirsutism
- Gingival hyperplasia
Key clinical trials
- Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS) (PHASE2)
- A Study to Learn if Study Medicines Called Cyclosporine and Clarithromycin Affect How the Body Processes the Other Study Medicine Called PF-07328948 in Healthy Adults (PHASE1)
- Combination of Eltrombopag With Immunosuppressive Therapy in East-Asian Patients With Severe Aplastic Anemia (PHASE2)
- Optimizing PTCy Dose and Timing (PHASE1, PHASE2)
- Safety and Efficacy of the JAK1 Inhibitor Combined With Intensive Immunosuppressive Therapy in Severe Aplastic Anemia (PHASE1, PHASE2)
- Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy (PHASE3)
- A Study to Learn if the Study Medicines Called Itraconazole and Cyclosporine Change How the Body Processes the Other Study Medicine Called Danuglipron in Healthy Adults. (PHASE1)
- A Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous Nephropathy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cyclosporin Capsules CI brief — competitive landscape report
- Cyclosporin Capsules updates RSS · CI watch RSS
- Shanghai JMT-Bio Inc. portfolio CI